News and Announcements
Prescient Therapeutics has Two New Patents Granted to Protect Lead Asset
- Published August 31, 2015 3:41PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
31st August 2015, ASX Announcement
Prescient Therapeutics (ASX:PTX), a clinical stage oncology company, has substantially bolstered its intellectual property portfolio with two new US patents granted to protect its lead asset PTX-200.
The first patent, US Patent 9,101,641, covers Prescient’s method for treating patients with tumours that overexpress AKT kinase, a key molecule in the oncogenic AKT signaling pathway.
Prescient’s lead drug PTX-200 is a novel small molecule that works by blocking the AKT pathway, and inhibiting tumour growth.
High AKT expression is associated with a poor prognosis, resistance to chemotherapy and shortened survival times in a range of cancers. Trials of PTX-200 are currently underway in the United States in patients with breast and ovarian cancers.
Further expanding the company’s IP portfolio is granted US Patent No. 9,115,162, which covers a propriety method for identifying and treating cancer patient with enhances sensitivity to PTX-200 through a direct measurement of AKT levels in the patients’s tumour. This patents further strengthens Prescient’s focus on “personalised medicine” whereby patients are selected based on their tumour blueprint and treated with a specific drug that targets such blueprint, hence increasing likelihood that a patient will respond to the drug. Personalised or tailored medicine is the way of the future, breaking the “one size fits all “approach to drug treatment that has seen many failures in the past.
To read the full announcement, please click here.
Company Updates
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
The Best of Both Worlds: How Omnique Fund is Rewiring Real World Assets via Tokenisation
For decades, the playbook for Australia’s wholesale investors has remained relatively unchanged: pick between the slow-moving, illiquid reliability of tangible assets like property and gold, or chase the frictionless, high-velocity liquidity of public equity and digital markets. But as macroeconomic volatility spikes and a structural housing deficit reshapes private debt demand, sophisticated investors are demanding […]
Backed By Leading Investment Groups and Family Offices
